Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis

Janus kinase inhibitors (JAKis) ruxolitinib, fedratinib, and pacritinib are the current standard of care in symptomatic myelofibrosis (MF). However, progressive disease and toxicities frequently lead to JAKi discontinuation. Preclinical data indicate that combining JAK and bromodomain and extratermi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Vikas, Mascarenhas, John, Kremyanskaya, Marina, Rampal, Raajit K., Talpaz, Moshe, Kiladjian, Jean-Jacques, Vannucchi, Alessandro M., Verstovsek, Srdan, Colak, Gozde, Dey, Debarshi, Harrison, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509667/
https://www.ncbi.nlm.nih.gov/pubmed/37530627
http://dx.doi.org/10.1182/bloodadvances.2023010628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509667/
https://www.ncbi.nlm.nih.gov/pubmed/37530627
http://dx.doi.org/10.1182/bloodadvances.2023010628

Ejemplares similares